FOLH1 and prostate cancer: Interestingly, it has been reported that the radioiodinated PSMA inhibitor [125I]I-DCIBzL has a high potential for clinical translation to treat prostate cancer, which was attributed to the perinuclear localization of this radioconjugate in PSMA-positive PCa cells [11,12,13].